Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer

被引：1

作者：

Bolla, M. ^{[1
]}

Fourneret, P. ^{[1
]}

Descotes, J. -L. ^{[2
]}

机构：

[1] CHU, Clin Univ Cancerol Radiotherapie, F-63011 Grenoble, France

[2] CHU, Clin Univ Urol, F-63011 Grenoble, France

来源：

BULLETIN DU CANCER | 2008年 / 95卷 / 12期

关键词：

high-risk prostate cancer; combination of external irradiation and androgen suppression;

D O I：

10.1684/bdc.2008.0755

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment of high-risk prostate cancer-localized or locally advanced-is based on the combination of external irradiation and hormonal treatment by LHRH analogue (aLHRH) according to the results of phases III randomized trials RTOG and/or EORTC trials. These trials show a significant improvement of overall or specific survival. Localized prostate cancer require 6-month complete androgen blockade, while locally advanced prostate cancer need a long-term hormonal treatment for a duration ranging from 2,5 to 3 years. Some trials, which have a long follow-up show that the risk of cardiovascular death is not significantly increased by hormonal treatment.

引用

页码：1213 / 1218

页数：6

共 50 条

[41] Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer
Philipson, Rebecca G.
Romero, Tahmineh
Wong, Jessica K.
Stish, Bradley J.
Dess, Robert T.
Spratt, Daniel E.
Pilar, Avinash
Reddy, Chandana
Wedde, Trude B.
Lilleby, Wolfgang A.
Fiano, Ryan
Merrick, Gregory S.
Stock, Richard G.
Demanes, D. Jeffrey
Moran, Brian J.
Braccioforte, Michelle
Tran, Phuoc T.
Martin, Santiago
Martinez-Monge, Rafael
Krauss, Daniel J.
Abu-Isa, Eyad I.
Valle, Luca
Chong, Natalie
Pisansky, Thomas M.
Choo, C. Richard
Song, Daniel Y.
Greco, Stephen
Deville, Curtiland
McNutt, Todd
DeWeese, Theodore L.
Ross, Ashley E.
Ciezki, Jay P.
Tilki, Derya
Karnes, R. Jeffrey
Klein, Eric A.
Tosoian, Jeffrey J.
Boutros, Paul C.
Nickols, Nicholas G.
Bhat, Prashant
Shabsovich, David
Juarez, Jesus E.
Kupelian, Patrick A.
Rettig, Matthew B.
Berlin, Alejandro
Tward, Jonathan D.
Davis, Brian J.
Reiter, Robert E.
Steinberg, Michael L.
Elashoff, David
Horwitz, Eric M.
EUROPEAN UROLOGY, 2021, 80 (02) : 142 - 146
[42] Validation of a subclassification for high-risk prostate cancer in a prospective cohort
Butler, Santino S.
Dee, Edward C.
Lamba, Nayan
Sha, Sybil T.
Mahal, Brandon A.
Whitbeck, Amanda
Makkar, Rishi
Wangoe, Janet
Mouw, Kent W.
Nguyen, Paul L.
Muralidhar, Vinayak
CANCER, 2020, 126 (10) : 2132 - 2138
[43] Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis
Guarneri, Alessia
Botticella, Angela
Filippi, Andrea Riccardo
Ruggieri, Andrea
Piva, Cristina
Munoz, Fernando
Ragona, Riccardo
Gontero, Paolo
Ricardi, Umberto
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (07) : 1141 - 1147
[44] Comparative effectiveness of treatments for high-risk prostate cancer patients
Jayadevappa, Ravishankar
Lee, David I.
Chhatre, Sumedha
Guzzo, Thomas J.
Malkowicz, Stanley B.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (09) : 574.e11 - 574.e18
[45] Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis
Chys, Brecht
Devos, Gaetan
Everaerts, Wouter
Albersen, Maarten
Moris, Lisa
Claessens, Frank
De Meerleer, Gert
Haustermans, Karin
Briganti, Alberto
Chlosta, Piotr
Gontero, Paolo
Graefen, Markus
Gratzke, Christian
Karnes, R. Jeffrey
Kneitz, Burkhard
Marchioro, Giansilvio
Salas, Rafael Sanchez
Spahn, Martin
Tombal, Bertrand
Van Der Poel, Henk
Walz, Jochen
Van Poppel, Hendrik
Joniau, Steven
FRONTIERS IN ONCOLOGY, 2020, 10
[46] Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy
Cheung, R
Tucker, SL
Dong, L
Kuban, D
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (05): : 1234 - 1240
[47] Predictors for late genitourinary toxicity in men receiving radiotherapy for high-risk prostate cancer using planned and accumulated dose
Ong, Ashley Li Kuan
Knight, Kellie
Panettieri, Vanessa
Dimmock, Mathew
Tuan, Jeffrey Kit Loong
Tan, Hong Qi
Wright, Caroline
PHYSICS & IMAGING IN RADIATION ONCOLOGY, 2023, 25
[48] REDEFINING HIGH-RISK PROSTATE CANCER BASED ON DISTANT METASTASES AND MORTALITY AFTER HIGH-DOSE RADIOTHERAPY WITH ANDROGEN DEPRIVATION THERAPY
Tendulkar, Rahul D.
Reddy, Chandana A.
Stephans, Kevin L.
Ciezki, Jay P.
Klein, Eric A.
Mahadevan, Arul
Kupelian, Patrick A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (04): : 1397 - 1404
[49] Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches
Marvaso, Giulia
Corrao, Giulia
Zaffaroni, Mattia
Pepa, Matteo
Augugliaro, Matteo
Volpe, Stefania
Musi, Gennaro
Luzzago, Stefano
Mistretta, Francesco Alessandro
Verri, Elena
Cossu Rocca, Maria
Ferro, Matteo
Petralia, Giuseppe
Nole, Franco
De Cobelli, Ottavio
Orecchia, Roberto
Jereczek-Fossa, Barbara Alicja
FRONTIERS IN ONCOLOGY, 2021, 11
[50] The association of type and number of high-risk criteria with cancer-specific mortality in prostate cancer patients treated with radical prostatectomy
Chierigo, Francesco
Flammia, Rocco Simone
Sorce, Gabriele
Hoeh, Benedikt
Hohenhorst, Lukas
Panunzio, Andrea
Tian, Zhe
Saad, Fred
Graefen, Marcus
Gallucci, Michele
Briganti, Alberto
Montorsi, Francesco
Chun, Felix K. H.
Shariat, Shahrokh F.
Antonelli, Alessandro
Guano, Giovanni
Mantica, Guglielmo
Borghesi, Marco
Suardi, Nazareno
Terrone, Carlo
Karakiewicz, Pierre I.
CURRENT UROLOGY, 2024, 18 (02) : 128 - 132

← 1 2 3 4 5 →